Health Condition 1: G409- Epilepsy, unspecified
Conditions
Interventions
Intervention1: Korocanai Mathirai along with Anda Thylam: One pill(130 mg)of Korocanai Mathirai along with 4 drops of Anda Thylam BD,after food for 60 days.
Intervention2: korocanai Mathirai along wit
Sponsors
National Institute Of Siddha
Eligibility
Inclusion criteria
Inclusion criteria: 1.NHS3 scale greater than 5 and less than 20 score. 2.Symptoms of at least two unprovoked seizures occurring at least 24 hours apart. 3.Known cases of epilepsy who are already on treatment.
Exclusion criteria
Exclusion criteria: 1.K/C/O Epileptic syndromes,status epilepticus 2.K/C/O Psychogenic non-epileptic seizures, Psychatric illness causing seizures 3.K/C/O Progressive neurological disease 4.K/C/O SOL, Meningitis ,encephalitis,Metabolic disturbance 5.K/C/O Hypersensitivity or known allergy. 6.K/C/O Severe hepatic impairment. 7.Pregnant and lactating women 8.K/H/O coronary heart diseases and other cardiac ailments. 9.K/H/O AIDS, Syphilis. 10.Active substance abuse/alcohol dependence in past 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in frequency and duration of seizure episode, reduction in recover time after an episode and duration of loss of consciousness, reduction in seizure severity will be assessed using NHS3 scaleTimepoint: 2 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.The quality of life of the patients receiving siddha anti-epileptic treatment (korocanai Mathirai with Anda Thailam) will be assessed using QOLIE-31 scale. 2.The remission duration and relapse of symptoms for the patient will be monitored. 3.Safety of the trial medicines through clinical assessment and laboratory investigations (LFT, RFT, CBC) will be monitored. Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Mary Sharmila C
National Institute of Siddha
Outcome results
None listed